Two Sigma Investments LP grew its stake in Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 41.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 891,279 shares of the company's stock after acquiring an additional 260,318 shares during the quarter. Two Sigma Investments LP owned about 0.39% of Gossamer Bio worth $806,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in the stock. Octagon Capital Advisors LP lifted its position in shares of Gossamer Bio by 99.7% in the fourth quarter. Octagon Capital Advisors LP now owns 18,350,000 shares of the company's stock valued at $16,599,000 after acquiring an additional 9,162,117 shares in the last quarter. Alyeska Investment Group L.P. lifted its position in shares of Gossamer Bio by 52.7% in the fourth quarter. Alyeska Investment Group L.P. now owns 8,808,514 shares of the company's stock valued at $7,968,000 after acquiring an additional 3,041,058 shares in the last quarter. Silverarc Capital Management LLC lifted its position in shares of Gossamer Bio by 9.3% in the fourth quarter. Silverarc Capital Management LLC now owns 6,171,847 shares of the company's stock valued at $5,583,000 after acquiring an additional 526,495 shares in the last quarter. Monaco Asset Management SAM lifted its position in shares of Gossamer Bio by 39.5% in the fourth quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company's stock valued at $4,859,000 after acquiring an additional 1,520,721 shares in the last quarter. Finally, Millennium Management LLC lifted its position in shares of Gossamer Bio by 14.6% in the fourth quarter. Millennium Management LLC now owns 3,586,067 shares of the company's stock valued at $3,244,000 after acquiring an additional 457,179 shares in the last quarter. 81.23% of the stock is currently owned by hedge funds and other institutional investors.
Gossamer Bio Trading Up 5.6%
Shares of NASDAQ GOSS opened at $1.33 on Friday. The company has a market cap of $302.31 million, a price-to-earnings ratio of -4.16 and a beta of 1.85. Gossamer Bio, Inc. has a 12-month low of $0.50 and a 12-month high of $1.55. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. The stock's 50 day simple moving average is $1.02 and its 200 day simple moving average is $1.03.
Gossamer Bio (NASDAQ:GOSS - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.02. The business had revenue of $9.89 million for the quarter, compared to the consensus estimate of $3.95 million. Equities research analysts expect that Gossamer Bio, Inc. will post -0.28 EPS for the current year.
Analyst Upgrades and Downgrades
GOSS has been the topic of several recent analyst reports. HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Gossamer Bio in a research report on Tuesday, March 18th. Wedbush reiterated an "outperform" rating and set a $4.00 target price on shares of Gossamer Bio in a research report on Friday, May 16th. Finally, The Goldman Sachs Group increased their target price on Gossamer Bio from $7.00 to $8.00 and gave the stock a "buy" rating in a research report on Friday, May 16th.
Read Our Latest Stock Analysis on GOSS
About Gossamer Bio
(
Free Report)
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Further Reading
Want to see what other hedge funds are holding GOSS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gossamer Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gossamer Bio wasn't on the list.
While Gossamer Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
